Fennec Posts $5.8M Q3 Adjusted EBITDA as PEDMARK Sales Scale
FENC sits 88% above its 52-week low of $5.65.
Summary
Fennec reported third-quarter adjusted EBITDA of $5.8 million, a profitability marker for a company that only recently crossed into the black, alongside third-quarter revenue of $19.6 million and sales up 56% to $19.4 million, with EPS of 12c. That follows Q2 2026 net product sales of $17.1 million, up 78% year-over-year, and a $2.0 million net profit — so the EBITDA figure suggests the PEDMARK ramp is holding. The setup matters because the September Phase 2 STS-J01 data in Japan showed hearing loss in 24.0% of patients versus 56.4% historically, giving the franchise a second growth leg if Japanese approval follows. With a market cap near $373 million, $5.8 million of quarterly adjusted EBITDA is a meaningful swing factor for valuation. Watch the full Q3 release for any update on the Japan regulatory path.
At the time of this announcement, FENC was trading at $10.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $373.1M. The 52-week trading range was $5.65 to $13.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.